In summary, our findings indicated that elevated levels of NLRP3/IL‐1β in tumor cells contribute to oxaliplatin resistance and tumor progression through the modulation of PMN‐MDSC recruitment and PD‐L1 expression. The gene discussed is NLRP3; the disease is neoplasm.